CRISPR Therapeutics Is Editing Out Its Correction

CRISPR Therapeutics Is Editing Out Its Correction
·2 min read

In our last review of CRISPR Therapeutics on March 23 we were bearish and recommended, "Avoid the long side of CRSP, as the charts and indicators point to the possibility of further steep losses." CRSP declined to a new low in early May, but has strengthened into June. In this daily bar chart of CRSP, below, we can see that prices have held above the chart support in the $90 area from July to early November.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting